Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

NCT02115295 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02115295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02115295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 19, 2014
Completion date
May 31, 2030
Enrollment
508 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute myeloid leukemia, blast phase chronic myelogenous leukemia, bcr-abl1 positive, blasts 10 percent or more of bone marrow nucleated cells, blasts 10 percent or more of peripheral blood white cells, de novo myelodysplastic syndrome, myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory acute myeloid leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia